These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 9516088)

  • 1. Antisense oligonucleotide therapeutics for human leukemia.
    Gewirtz AM
    Crit Rev Oncog; 1997; 8(1):93-109. PubMed ID: 9516088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense oligonucleotide therapeutics for human leukemia.
    Gewirtz AM
    Curr Opin Hematol; 1998 Jan; 5(1):59-71. PubMed ID: 9515205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oligonucleotide therapeutics for human leukaemia.
    Gewirtz AM
    Ciba Found Symp; 1997; 209():169-91; discussion 191-4. PubMed ID: 9383576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides.
    Skorski T; Nieborowska-Skorska M; Wlodarski P; Perrotti D; Hoser G; Kawiak J; Majewski M; Christensen L; Iozzo RV; Calabretta B
    J Natl Cancer Inst; 1997 Jan; 89(2):124-33. PubMed ID: 8998181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides.
    Ratajczak MZ; Kant JA; Luger SM; Hijiya N; Zhang J; Zon G; Gewirtz AM
    Proc Natl Acad Sci U S A; 1992 Dec; 89(24):11823-7. PubMed ID: 1281545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene-targeted specific inhibition of chronic myeloid leukemia cell growth by BCR-ABL antisense oligodeoxynucleotides.
    Skórski T; Szczylik C; Malaguarnera L; Calabretta B
    Folia Histochem Cytobiol; 1991; 29(3):85-9. PubMed ID: 1794439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense BCR-ABL oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173.
    Smetsers TF; Skorski T; van de Locht LT; Wessels HM; Pennings AH; de Witte T; Calabretta B; Mensink EJ
    Leukemia; 1994 Jan; 8(1):129-40. PubMed ID: 8289478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide.
    Skorski T; Nieborowska-Skorska M; Nicolaides NC; Szczylik C; Iversen P; Iozzo RV; Zon G; Calabretta B
    Proc Natl Acad Sci U S A; 1994 May; 91(10):4504-8. PubMed ID: 8183938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of bcr-abl antisense oligonucleotide on DNA synthesis and apoptosis in K562 chronic myeloid leukemia cells.
    Rowley PT; Keng PC; Kosciolek BA
    Leuk Res; 1996 Jun; 20(6):473-80. PubMed ID: 8709619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense strategies in the treatment of leukemias.
    Calabretta B; Skorski T; Ratajczak MZ; Gewirtz AM
    Semin Oncol; 1996 Feb; 23(1):78-87. PubMed ID: 8607034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential therapeutic applications of antisense oligodeoxynucleotides in the treatment of chronic myelogenous leukemia.
    Gewirtz AM
    Leuk Lymphoma; 1993; 11 Suppl 1():131-7. PubMed ID: 7504543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antisense inhibition of P210 bcr-abl in chronic myeloid leukemia.
    Vaerman JL; Lewalle P; Martiat P
    Stem Cells; 1993 Oct; 11 Suppl 3():89-95. PubMed ID: 8298481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unmodified phosphodiester antisense oligodeoxynucleotides to the BCR-ABL junction do not suppress Philadelphia-positive clonogenic cells.
    Käbisch A; Pérènyi L; Seay U; Lohmeyer J; Pralle H
    Acta Haematol; 1994; 92(4):190-6. PubMed ID: 7701917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphorothioate BCR-ABL antisense oligonucleotides induce cell death, but fail to reduce cellular bcr-abl protein levels.
    Smetsers TF; van de Locht LT; Pennings AH; Wessels HM; de Witte TM; Mensink EJ
    Leukemia; 1995 Jan; 9(1):118-30. PubMed ID: 7845006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oligonucleotide therapeutics: clothing the emperor.
    Gewirtz AM
    Curr Opin Mol Ther; 1999 Jun; 1(3):297-306. PubMed ID: 11713794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An antisense Bcr-Abl phosphodiester-tailed methylphosphonate oligonucleotide reduces the growth of chronic myeloid leukaemia patient cells by a non-antisense mechanism.
    Smetsers TF; Linders EH; van de Locht LT; de Witte TM; Mensink EJ
    Br J Haematol; 1997 Feb; 96(2):377-81. PubMed ID: 9029029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poor cellular uptake of antisense oligodeoxynucleotides: an obstacle to their use in chronic myeloid leukaemia.
    Clark RE
    Leuk Lymphoma; 1995 Oct; 19(3-4):189-95. PubMed ID: 8535209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction.
    Mahon FX; Ripoche J; Pigeonnier V; Jazwiec B; Pigneux A; Moreau JF; Reiffers J
    Exp Hematol; 1995 Dec; 23(14):1606-11. PubMed ID: 8542954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Computer aid design of antisense oligonucleotide in gene therapy--review].
    Wu QW; Wu JJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Jun; 12(3):387-91. PubMed ID: 15228675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ribonuclease H-mediated antisense effects in intact human leukaemia cells.
    Tidd DM
    Biochem Soc Trans; 1996 Aug; 24(3):619-23. PubMed ID: 8878815
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.